Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (MXCT) pioneers advanced cell engineering through its proprietary Flow Electroporation technology, enabling breakthroughs in gene therapy and biopharmaceutical development. This dedicated news hub provides investors and industry professionals with essential updates on MXCT’s strategic initiatives, financial performance, and scientific advancements.
Access timely press releases covering regulatory milestones, partnership announcements, and technology innovations. Our curated collection includes earnings reports, clinical trial updates, and analyses of MXCT’s role in advancing next-generation cell therapies. The platform serves as a critical resource for tracking the company’s impact on precision medicine and scalable therapeutic manufacturing.
Discover updates about MXCT’s ExPERT platform deployments, licensing agreements with biotech innovators, and expansions in global research collaborations. Content is organized for quick scanning while maintaining technical accuracy, ensuring relevance for both casual observers and specialized analysts.
Bookmark this page for streamlined access to verified MXCT developments. Combine our news feed with Stock Titan’s financial tools to monitor how MaxCyte’s cell engineering leadership translates into long-term market positioning.
MaxCyte (NASDAQ: MXCT), a cell-engineering platform technology company, has scheduled its first quarter 2025 financial results announcement for May 7th, 2025, after the U.S. market close. The company will host a conference call with management at 4:30 p.m. Eastern Time to discuss the quarterly performance.
Investors interested in participating in the earnings call must register online, preferably at least one day in advance. A live webcast and recording of the event will be accessible through the 'Events' section on MaxCyte's investor relations website.
MaxCyte (NASDAQ: MXCT) reported Q4 and full year 2024 financial results, showing mixed performance. Q4 total revenue decreased 45% to $8.7M compared to Q4 2023, primarily due to one-time approval milestones in the previous year. However, core business revenue grew 20% to $8.6M in Q4 2024.
For the full year 2024, total revenue decreased 6% to $38.6M, while core business revenue increased 9% to $32.5M. The company maintained strong liquidity with $190.3M in cash and investments. MaxCyte expanded its Strategic Platform License (SPL) portfolio to 28 active agreements, including 18 clinical programs and 1 commercial program.
Looking ahead, MaxCyte provided 2025 guidance projecting core revenue growth of 8-15% and expecting approximately $5M in SPL Program-related revenue. The company anticipates ending 2025 with $160M in total cash and investments.
MaxCyte (MXCT) has entered into a strategic platform license agreement with TG Therapeutics for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The partnership aims to support the development and commercialization of azer-cel, TG's allogeneic CD19 CAR T cell therapy program for autoimmune diseases.
Under the agreement, TG Therapeutics receives non-exclusive research, clinical and commercial rights, while MaxCyte will receive annual licensing fees and program-related revenue. TG Therapeutics recently acquired worldwide license to azer-cel from Precision BioSciences and has received FDA clearance for an IND application in progressive forms of multiple sclerosis (MS), with Phase 1 trials targeted for 2025.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a cell-engineering platform technology company, has announced it will release its fourth quarter and full year 2024 financial results after U.S. market close on March 11th, 2025. The company will host a conference call with management to discuss the results at 4:30 p.m. Eastern Time on the same day.
Additionally, MaxCyte management will participate in the 45th Annual TD Cowen Healthcare Conference, delivering a fireside chat on March 3rd at 10:30 a.m. ET. Both events will be accessible via webcast through the company's investor relations website.
MaxCyte (MXCT) has acquired SeQure Dx, a leader in on-target and off-target editing assessment services for cell and gene therapies, for an initial $4.5 million in cash with potential additional contingent payments up to $2.5 million based on revenue targets.
SeQure Dx, headquartered in Waltham, Massachusetts, specializes in assays for editing confirmation and risk assessment across viral and non-viral gene editing modalities. The acquisition aims to strengthen MaxCyte's position in serving cell and gene therapy developers with tools spanning R&D through commercialization.
SeQure Dx generated approximately $1.7 million in revenue and incurred a $6.5 million loss in 2024 (based on unaudited results through November). The company transitioned from an assay development and licensing organization to a contract service provider in March 2024. MaxCyte expects improved financial performance through service revenue activity, cost synergies, and operational efficiencies.
MaxCyte (NASDAQ: MXCT) has released preliminary unaudited financial results for Q4 and full year 2024. The company expects Q4 core revenue between $8.3-8.5 million, up from $7.2 million in Q4 2023. Full-year core revenue is anticipated at $32.2-32.4 million, showing 8-9% growth compared to $29.8 million in 2023.
The company's cash position as of December 31, 2024, is expected to be approximately $190 million, exceeding both initial guidance of $175 million and updated December guidance of $185 million, though down from $211 million at the end of 2023.
In 2024, MaxCyte added six new SPL customers and supported the commercial launch of the first FDA-approved non-viral gene edited cell therapy product. Complete SPL program-related revenue and total revenue figures for Q4 and full year 2024 will be reported in March 2025.
MaxCyte (MXCT) announced that Board Member Art Mandell will retire effective December 31, 2024, after serving since 2006. Following his departure, the board will consist of nine directors. During Mandell's tenure, MaxCyte achieved significant milestones including its IPO on UK AIM and US Nasdaq, launched the ExPERT™ platform, secured 29 Strategic Platform Licenses with cell and gene therapy companies, and supported the industry's first FDA-approved CRISPR edited non-viral cell therapy. Board Chairman Richard Douglas acknowledged Mandell's contributions in positioning MaxCyte as a leader in cell engineering.
MaxCyte announced operational streamlining following an internal review initiated after appointing Maher Masoud as CEO. The company reduced its workforce by 15%, affecting 21 positions globally, aiming to enhance efficiency and align resources with strategic priorities. The restructuring is expected to generate $5.8 million in cost savings in 2025.
The company raised its 2024 core revenue growth guidance to 6-8% compared to 2023. MaxCyte expects to end 2024 with 116 employees, down from 143 at the end of 2023. SPL Program-related revenue is projected at $6 million, excluding revenue from Vertex/CRISPR's CASGEVY™. The company anticipates ending 2024 with approximately $185 million in cash and equivalents.
MaxCyte celebrates its 25th anniversary as a pioneer in non-viral cell engineering technologies. The company's Flow Electroporation® technology played a important role in developing CASGEVY®, the first FDA-approved non-viral cell therapy, in collaboration with Vertex Pharmaceuticals and CRISPR Therapeutics. MaxCyte has established 29 Strategic Platform License agreements across various therapeutic areas.
In 2022, the company relocated to a 67,000 square-foot facility in Maryland's I-270 biotech corridor, expanding its manufacturing capacity and research capabilities. Under CEO Maher Masoud's leadership, MaxCyte continues to advance its proprietary ExPERT™ platform, supporting customers in developing next-generation cell therapeutics.
MaxCyte (NASDAQ: MXCT) reported Q3 2024 financial results with total revenue of $8.2 million, up 2% year-over-year. Core business revenue increased 23% to $8.1 million, driven by 39% growth in cell therapy revenue to $6.5 million. The company signed six new Strategic Platform License (SPL) partners year-to-date, bringing total SPL partners to 29. Cash position remained strong at $196.6 million. Updated 2024 guidance projects core business revenue growth of at least 5% and SPL Program-related revenue of approximately $6 million. The company is considering delisting from AIM to focus on NASDAQ listing.
